Phenyl Aminosalicylate

Summary

Phenyl Aminosalicylate (CHEMBL1200868) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 229.23 Da · C13H11NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200868
Name	Phenyl Aminosalicylate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	8609
Molecular formula	C13H11NO3
Molecular weight	229.23
InChIKey	DNVVZWSVACQWJE-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)OC(=O)C2=C(C=C(C=C2)N)O

IUPAC name: phenyl 4-amino-2-hydroxybenzoate

Also known as: Fenamisal, NSC-40144, Pheny-pas-tebamin, Phenyl aminosalicylate, SID26749950, PHENYL AMINOSALICYLATE, SID144205091, SID170465273, fenamisal

Patent coverage: 434 distinct patent families (1,593 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,585 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 15 (assay-derived). Sample: Microtubule-associated protein tau, Survival motor neuron protein, Prelamin-A/C, Ferritin light chain, Protein deacetylase HDAC6, Thromboxane A2 receptor, Muscarinic acetylcholine receptor M1, Sodium-dependent noradrenaline transporter, Alpha-1A adrenergic receptor, Sodium-dependent dopamine transporter.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 16 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC6A3	6.63	AC50	235.2	nM	CHEMBL_ACT_25124967
SLC6A2	6.11	AC50	776.7	nM	CHEMBL_ACT_25146008
LMNA	6.05	Potency	891.3	nM	CHEMBL_ACT_3648806
HDAC6	5.73	IC50	1857	nM	CHEMBL_ACT_23141080
MAPT	5.5	Potency	3162	nM	CHEMBL_ACT_4026091
TP53	5	Potency	10000	nM	CHEMBL_ACT_4854081

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).